Evonetix expands to develop its desktop DNA synthesis platform
15,000 sq. ft of laboratory and office space will enable continued growth and development of the company’s integrated desktop platform for DNA synthesis.
Evonetix has moved to Coldham’s Business Park, Cambridge, UK. The new facility will enable the continued growth of the company as it continues in its mission to develop a desktop DNA synthesis platform based on its proprietary silicon chip.
Evonetix, previously based at Chesterford Research Park, now occupies 15,000 sq. ft at Coldham’s Business Park, comprising 8,000 sq. ft of fully fitted and equipped state-of-the art laboratory space and 7,000 sq. ft of office space all under one roof. This enables the company’s teams of physicists, electronics and software engineers, chemists, biologists and molecular biologists to work more closely together in a multidisciplinary approach to deliver the Evonetix mission. Headcount currently stands at 40, including 26 PhD biologists, physicists, chemists and engineers, and the company is currently looking to recruit further staff, including biophysicists, electronics and protein engineers.
The company’s silicon chip is made by MEMS processing and controls the synthesis of DNA at many thousands of independently controlled reaction sites or ‘pixels’ on the chip surface in a highly parallel fashion. This is compatible with both chemical and enzymatic DNA synthesis. Following synthesis, strands are assembled on-chip into double-stranded DNA in a process that identifies and removes errors, enabling accuracy, scale and speed that is several orders of magnitude better than conventional approaches.
Dr Tim Brears, Evonetix CEO, said: “Synthetic biology has the potential to solve some of the world’s most intractable problems, but we require innovation in gene synthesis to accelerate progress. Our new office and lab space will enable integration of our teams of specialists to support the development and delivery of our highly parallel desktop platform, which will be available to every researcher to accelerate their ability to use biology on a scale not currently possible.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...